Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Stopped early · Phase 2

Conditions studied: Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer

In brief

This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.

Key facts

Study ID

NCT00848783

Run by

NYU Langone Health

People needed

8

Starts

2008-05-01

Expected to finish

2012-09-01

Last updated by the study team

2018-01-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Norris Cancer Center — Los Angeles, California, United States
• Bellevue Hospital — New York, New York, United States
• NYU Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.